13. Oliver tells ACIP members: You'll need to think about the population level risk-benefit analysis & the individual level risk-benefit analysis Therein lies the rub.
-
Show this thread
-
14. What's that look like? This.pic.twitter.com/vL8Po6zdTY
4 replies 20 retweets 78 likesShow this thread -
15. Another look at the risks-benefits. These estimates are per month.pic.twitter.com/rzwDb8NRZn
6 replies 24 retweets 64 likesShow this thread -
16. (Broke my thread. Repeating to fix.) What is ACIP going to recommend today? Here are the options presented to them, from ACIP's Covid vaccine work group. Almost certainly going to be one of these. No debate yet, so can't say how the committee is leaning. But watch #4.pic.twitter.com/ICv95nvm1b
2 replies 16 retweets 49 likesShow this thread -
17. It's still early in the discussion period but so far support seems to be coalescing around option #4.
1 reply 6 retweets 33 likesShow this thread -
19. Beth Bell, chair of ACIP's Covid vaccine work group, stressed that the decision taken today is to come up with a policy for now, not for always. (This gets to
@DocJeffD's comment about the risk-benefit ratio changing when Covid transmission is lower in the US.)1 reply 4 retweets 38 likesShow this thread -
20. Listening to ACIP's deep dive into risks & benefits of the J&J vaccine reminds one of how amazing the US advisory committee system for HHS agencies is. VRBPAC (FDA) & ACIP (CDC) kick tires in public. This is unique and very valuable.
3 replies 27 retweets 125 likesShow this thread -
Replying to @HelenBranswell
I was thinking this must be like therapy for
@kakape after the EMA pressers.2 replies 1 retweet 9 likes -
Replying to @zeynep @HelenBranswell
You have no idea! This is the pandemic version of movie night for me ;)
2 replies 2 retweets 24 likes
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.